http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 03 Sep 2026 06:58:06 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Halozyme+Therapeutics+%28HALO%29/27021715.html <p>H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $115.00 price target on Halozyme Therapeutics (NASDAQ: HALO).</p><p>The analyst commented: "ALT-B4 competitive dynamics heighten with Novartis deal; recent ENHANZE deal flow argues against displacement. Novartis signed an option and license agreement with Alteogen covering subcutaneous (subQ) versions of multiple Novartis drugs using ALT-B4, with up to $3.223B if all options are exercised and milestones are achieved. We think Merck & Co. and now Novartis give ALT-B4 two major-pharma reference points, a net negative for ENHANZE because prospective partners increasingly have a credible alternative for subQ conversion. Though last year it http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Halozyme+Therapeutics+%28HALO%29/27021715.html Thu, 03 Sep 2026 06:58:06 -0400 HALO http://www.streetinsider.com/SEC+Filings/Form++3++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+14++Filed+by%3A+Appelhans+Dannielle/26962166.html si-local-file:///var/storage/secattach/20260821/26962166.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+14++Filed+by%3A+Appelhans+Dannielle/26962166.html Fri, 21 Aug 2026 16:55:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+14++Filed+by%3A+Appelhans+Dannielle/26962166.html si-local-file:///var/storage/secattach/20260821/26962166.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+14++Filed+by%3A+Appelhans+Dannielle/26962166.html Fri, 21 Aug 2026 16:55:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+17++Filed+by%3A+Torley+Helen/26951585.html si-local-file:///var/storage/secattach/20260819/26951585.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+17++Filed+by%3A+Torley+Helen/26951585.html Wed, 19 Aug 2026 20:01:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+17++Filed+by%3A+Torley+Helen/26951585.html si-local-file:///var/storage/secattach/20260819/26951585.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+17++Filed+by%3A+Torley+Helen/26951585.html Wed, 19 Aug 2026 20:01:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+14/26944127.html si-local-file:///var/storage/secattach/20260818/26944127.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+14/26944127.html Tue, 18 Aug 2026 16:04:00 -0400 HALO O.00978404 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+14/26944127.html si-local-file:///var/storage/secattach/20260818/26944127.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HALOZYME+THERAPEUTICS%2C++++For%3A+Aug+14/26944127.html Tue, 18 Aug 2026 16:04:00 -0400 HALO O.00978404 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259 http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html <p>Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, according to a company press release dated Aug. 18, 2026.</p> <p>Appelhans has served as President and Chief Executive Officer of COUR Pharmaceuticals, a private biotechnology company focused on autoimmune disease therapies, since 2023. During her tenure there, she helped negotiate a strategic collaboration with Genentech valued at up to $1 billion.</p> <p>Prior to COUR Pharmaceuticals, Appelhans served as Chief Executive Officer of Rubius Therapeutics, Inc., a publicly traded clinical-stage biopharmaceutical company. She also held senior roles at Novartis, including Senior Vice President and Chief Technical Officer http://www.streetinsider.com/Board+Changes/Halozyme+adds+biotech+executive+Appelhans+to+its+board/26944040.html Tue, 18 Aug 2026 16:01:32 -0400 A.03350906 A.10141387 A.30035300 A.40151759 A.50114092 A.50114145 A.50214881 A.50216867 HALO O.00050368 O.00978404 O.01868273 O.10045310 O.20059298 O.20947283 O.22593464 O.23618244 O.41497259